Skip to main content
. 2013 Feb 13;12(4):1005–1016. doi: 10.1074/mcp.O112.026617

Fig. 4.

Fig. 4.

Impact of the N-glycoprotein SRMAtlas on the biomarker pipeline. The general biomarker pipeline consists of the generation of a candidate list and a lengthy and expensive development time of antibody-based assays for the validation of the candidates in clinical specimen like blood plasma. The N-glycoprotein SRMAtlas now accelerates this validation phase, because the assays for candidate quantification are publicly available. Additionally, in comparison with the gold-standard ELISA, the SRM technology facilitates multiplexed measurements of any set of candidates.